https://mdmpathway.com/wellbei....ng-outcomes-of-a-wil
A pilot, phase I learn tested the safety and feasibility of a prime-boost immunization program based on V935, an adenoviral type 6 vector vaccine expressing a modified type of hTERT, administered alone or in combination with V934, a DNA plasmid that also conveys similar antigen and it is delivered with the electroporation shot technique. METHODS procedures Group #1 obtained two doses (low-dose 0.5 × 109 vg, and high-dose 0.5 × 1011 vg) of V935 followed closel
Like
Comment
Share
